Related Experiment Video
Updated: Jul 11, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Palliative Care in Children with Inherited Metabolic Diseases: Why does it matter?
Joana Pereira Mendes1, Andreia Nogueira1, Ema Grilo1
1Paediatric Palliative Care Team, Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Portugal.
Insights
Paediatric palliative care teams (PPCT) support children with inherited metabolic diseases (IMD) at home and in end-of-life planning. Referral to PPCTs reduced emergency department admissions, offering crucial emotional and bereavement support to families.
Area of Science:
- Pediatric Palliative Care
- Inherited Metabolic Diseases
- Healthcare Resource Utilization
Background:
- Inherited metabolic diseases (IMD) impose significant burdens on children and families, with challenges in symptom identification, prognostic uncertainty, and bereavement.
- Literature on the impact of paediatric palliative care (PPC) for these complex cases is limited.
Purpose of the Study:
- To evaluate children with IMD referred to a PPC team (PPCT).
- To analyze the impact of PPCT on home care, treatment limitations, hospital resource use, and end-of-life support.
Main Methods:
- Retrospective cohort study of children with IMD referred to a specialized PPCT from 2016-2022.
- Assessed clinical data including symptom control, referral timing, follow-up duration, treatment limitations, device dependency, hospital resource use (prior to and after referral), place of death, and end-of-life support.
Main Results:
- Fifteen children with IMD (median age 7 years) were referred to PPCT; 73% received home PPC and 80% had planned limitations on treatment.
- A decrease in emergency department admissions was observed post-referral (10 vs 2), though hospital and intensive care admissions remained similar.
- Six children died during the study period, all with planned treatment limitations, and 67% received PPCT support at end-of-life, with families receiving emotional and bereavement support.
Conclusions:
- Children with severe, complex IMD require extensive medical support and consume significant healthcare resources.
- Communication impairments in non-verbal children pose challenges for symptom assessment.
- PPCT referral facilitated home support, advance care planning, and reduced emergency visits, highlighting the need for a holistic approach to PPC for children with IMD.
Background:
Inherited metabolic diseases (IMD) bring considerable burden on the child and family. Challenging areas for health care include the identification of distressing symptoms, prognostic uncertainty, and bereavement. Literature regarding the impact of paediatric palliative care (PPC) is scarce.
Objective:
This study aims to evaluate children with IMD referred to a PPC team (PPCT) and to analyse its impact on home care, decision to limit treatment (DLT), use of hospital resources (emergency department admissions - EDA, hospital admissions - HA, intensive care admissions - ICA) and end of life support.
Methods:
Retrospective cohort study of children with IMD referred to a specialized PPCT (2016-2022). We assessed clinical data: symptoms control, time of referral and length of the follow-up period, DLT, device dependency, use of hospital resources prior to and after referral, place of death and end-of-life support.
Results:
Fifteen children with IMD were referred to PPCT (8% of total referrals), with median age of 7 years (4 months - 17 years); 53% female. All children were non or pre-verbal. Most prevalent symptoms were neurologic and motor impairment (100%), respiratory and gastrointestinal (75%). 80% had tube feeding, 90% had some respiratory device (non-invasive ventilation in 23%). All children had multidrug use, with a mean of 6 drugs per child (2-9). 73% had home PPC and 80% had DLT planned. Nine children died (78% in hospital), after a mean of 17 months of follow-up (2 months to 4 years), all with DLT planned. 67% had support from PPCT at the end of life. All these families received emotional support. Decrease in EDA (10 vs 2) was noticed before and after PPCT. No impact was seen in HA and ICA (6 vs 5 and 1 vs 1, respectively) and there was a longer mean of hospitalisation stay (15 vs 32 days).
Conclusion:
Our cohort includes a group of children with severe, complex and neurodegenerative IMD. They need multiple medications for symptoms control, are highly dependent on medical devices and consume significant healthcare resources. Communication impairment adds complexity being a major barrier to symptom assessment. PPCT referral allowed home support, anticipated care plans development with end of life and bereavement support, as well as a tendency towards a reduction in EDA. These findings reinforce the need for holistic approach to identify and address the PPC needs of children with IMD.
More Related Videos
09:02Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
06:53Visualization of Mitochondrial Respiratory Function using Cytochrome C Oxidase / Succinate Dehydrogenase COX/SDH Double-labeling Histochemistry
Published on: November 23, 2011
Related Concept Videos
Inborn Errors of Metabolism
Continuing Care
Lysosomal Hydrolases
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Chronic Pancreatitis II: Collaborative Care
Assessment: